Does THC Treatment for Tourette Syndrome Cause Cognitive Problems?

This was a randomized, double-blind, placebo-controlled crossover trial. Twelve adult Tourette syndrome patients received either a single dose of THC (5-10 mg) or placebo, then crossed over to the other condition. A comprehensive battery of neuropsychological tests assessed multiple cognitive domains. The Symptom Checklist 90-R was used to assess behavioral and mood changes.

One of the major concerns about using THC therapeutically is the potential for cognitive side effects. This study provided early evidence that cognitive impairment observed in recreational users may not apply to patients using THC for specific medical conditions, potentially because the therapeutic context, dose, and patient population differ from recreational use scenarios.

This study was part of a growing body of research suggesting THC could be beneficial for Tourette syndrome tics and behavioral symptoms. The finding that therapeutic doses did not impair cognition helped address a key safety concern that could otherwise limit clinical adoption. Subsequent larger trials have continued to explore cannabinoids for Tourette syndrome.

The sample size of 12 patients was small and limited statistical power to detect subtle cognitive effects. Only a single dose was tested, so the cognitive safety of longer-term THC treatment remains unaddressed by this study. The crossover design, while efficient, can be complicated by carryover effects. The increase in obsessive-compulsive behavior scores is difficult to interpret given the acknowledged limitations of the assessment tool used.